US2003113334A1PendingUtilityA1

Therapeutic agent for lymphatic tumors

54
Assignee: CHUGAI PHARMACEUTICAL CO LTDPriority: Feb 12, 1997Filed: Dec 10, 2002Published: Jun 19, 2003
Est. expiryFeb 12, 2017(expired)· nominal 20-yr term from priority
Inventors:Yasuo KoishiharaYasushi Yoshimura
C07K 14/47A61K 38/00A61P 35/02C07K 2317/734A61K 2039/505C07K 16/3061C07K 2317/24A61P 35/00A61K 39/395
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A therapeutic agent for lymphatic tumors (excluding myeloma) comprising as an active ingredient an antibody that specifically binds to a protein having the amino acid sequence as set forth in SEQ ID NO: 1 and that has a cytotoxic activity.

Claims

exact text as granted — not AI-modified
1 . A therapeutic agent for lymphatic tumors (excluding myeloma) comprising as an active ingredient an antibody that specifically binds to a protein having the amino acid sequence as set forth in SEQ ID NO: 1 and that has a cytotoxic activity.  
     
     
         2 . A therapeutic agent according to  claim 1  wherein the lymphatic tumor is T cell tumor.  
     
     
         3 . A therapeutic agent according to  claim 1  wherein the lymphatic tumor is B cell tumor (excluding myeloma).  
     
     
         4 . A therapeutic agent according to  claim 1  wherein the antibody is a monoclonal antibody.  
     
     
         5 . A therapeutic agent according to  claim 1  wherein the cytotoxic activity is an ADCC activity.  
     
     
         6 . A therapeutic agent according to  claim 1  wherein the cytotoxic activity is a CDC activity.  
     
     
         7 . A therapeutic agent according to  claim 4  wherein the antibody has a human antibody constant region Cγ.  
     
     
         8 . A therapeutic agent according to  claim 7  wherein the human antibody constant region Cγ is Cγ1 or Cγ3.  
     
     
         9 . A therapeutic agent according to  claim 4  wherein the antibody is anti-HM1.24 antibody.  
     
     
         10 . A therapeutic agent according to  claim 4  wherein the antibody is a chimeric antibody or a humanized antibody.  
     
     
         11 . A therapeutic agent according to  claim 9  wherein the antibody is a chimeric anti-HM1.24 antibody.  
     
     
         12 . A therapeutic agent according to  claim 9  wherein the antibody is a humanized anti-HM1.24 antibody  
     
     
         13 . A therapeutic agent according to  claim 1  wherein the antibody specifically binds to an epitope recognized by anti-HM1.24 antibody.  
     
     
         14 . An antibody that specifically binds to a protein having the amino acid sequence as set forth in SEQ ID NO: 1 and that has a cytotoxic activity.  
     
     
         15 . An antibody according to  claim 13  wherein the cytotoxic activity is an ADCC activity.  
     
     
         16 . An antibody according to  claim 13  wherein the cytotoxic activity is a CDC activity.

Join the waitlist — get patent alerts

Track US2003113334A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.